The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

On Monday, Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations ... to research and develop cancer treatments. Under this new agreement, the parties will leverage AdvanCell's proprietary ...

We came across a bullish thesis on Eli Lilly and Company (LLY ... which is set to expand into new therapeutic areas. Despite increasing competition, the company remains strong in both the U.S ...

In Q4 2024, Eli Lilly’s top-performing drugs included Mounjaro, which saw a 60% increase in revenue, and Zepbound, which is set to expand into new therapeutic areas. Despite increasing competition, ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

potentially generating over 3.7 million new prescriptions annually. This regulatory milestone could significantly increase the drug’s market potential. Eli Lilly and Company (NYSE:LLY ...

today announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly and Company to research and develop innovative treatments for various cancers. Under this new ...